Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | Director | June 04, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZEVRA THERAPEUTICS, INC.
Report date June 04, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2036-06-03 | Direct | 30,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.
F2: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.
F3: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
G1 Therapeutics, Inc.
Report date September 18, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-09-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-18 · Disposition to issuer · Disposed 20,000 · Balance 10,000 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Row 2 · 2024-09-18 · Other · Disposed 10,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2032-06-23 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration").
F2: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 10,584 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 35,340 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 16,548 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 3,144 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 34,416 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 22,464 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: These stock options were granted with automatic vesting on exercisable date.
JUNIPER PHARMACEUTICALS INC
Report date August 14, 2018 · Filed August 15, 2018
Section 16 reporting ended · disclosed 2018-08-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 1
1 source rowRow 1 · 2018-08-14 · Disposition to issuer · Disposed 103,855 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price"). F2: Includes 87,650 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 87,650 restricted stock units was cancelled in exchange for the Offer Price. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.90 · Expires 2025-02-09 | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-14 · Disposition to issuer · Disposed 110,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.15 · Expires 2024-03-03 | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-14 · Disposition to issuer · Disposed 127,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. |
| Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.59 · Expires 2023-07-20 | Direct | 0 |
Reported balance
After 2018-08-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-08-14 · Disposition to issuer · Disposed 225,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
F2: Includes 87,650 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 87,650 restricted stock units was cancelled in exchange for the Offer Price.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options.
Orchard Therapeutics plc
Report date January 24, 2024 · Filed January 24, 2024
Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.48 · Expires 2032-06-06 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-24 · Disposition to issuer · Disposed 46,000 · Balance 0 F1: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F2: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-13 | Direct | 0 |
Reported balance
After 2024-01-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-24 · Disposition to issuer · Disposed 105,000 · Balance 0 F1: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F2: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.
F2: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 18, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001434647-26-000054 · wk-form4_1781813773.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-03 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. F2 · shares: This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 02, 2025 Filed Dec 9, 2025 21:18 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001584516-25-000009 · wk-form4_1765315079.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-12-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, December 2, 2025. F2 · derivative.exercise_date: The option will vest and become exercisable as follows: (1) in three equal installments on the each of the dates that are one day prior to the first three annual stockholder meetings occurring after the grant date, or (2) immediately prior to a Change in Control, subject in each case to the director's continued service on such vesting date. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $5.30 | Not disclosed |
DisclosureSEC source: 0000950170-24-107799 · ownership.xml · derivative · entry 5 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2032-06-23 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.83 | Not disclosed |
DisclosureSEC source: 0000950170-24-107799 · ownership.xml · derivative · entry 4 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2033-06-15 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.99 | Not disclosed |
DisclosureSEC source: 0000950170-24-107799 · ownership.xml · derivative · entry 3 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2034-06-13 F4 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | OtherCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107799 · ownership.xml · nonDerivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. Read SEC document |
| September 18, 2024 Filed Sep 18, 2024 16:15 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | Disposition to issuerCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107799 · ownership.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2 · kind: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2 · price: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:42 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001562180-24-005083 · primarydocument.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-13 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 16:42 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005083 · primarydocument.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 13, 2024, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 10,000 shares of common stock; (ii) 10,000 RSUs from award granted on June 15, 2023; and (iii) 10,000 RSUs from award granted on June 13, 2024. Read SEC document |
| January 24, 2024 Filed Jan 24, 2024 22:34 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | Disposition to issuerStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-24-007089 · ownership.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 105,000 shares Expires 2033-06-13 F1 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F2 · derivative.exercise_date: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares. Read SEC document |
| January 24, 2024 Filed Jan 24, 2024 22:34 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000950170-24-007089 · ownership.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 46,000 shares Expires 2032-06-06 F1 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023. F2 · derivative.exercise_date: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:06 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001562180-23-005266 · primarydocument.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-15 F4 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 16:06 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005266 · primarydocument.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 15, 2023, subject to the Reporting Person's continued service as a director. The Reporting Person has elected to defer vesting of these shares pursuant to the G1 Therapeutics, Inc. Deferred Compensation Plan for Non-Employee Directors. The RSUs will vest upon termination of the Reporting Person's service as a Director on the Company's Board. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. F3 · balance_after: Represents (i) 10,000 RSUs from award granted on June 23, 2022; and (ii) 10,000 RSUs from award granted on June 15, 2023. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:30 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001209191-23-037905 · doc4.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Ordinary Shares · 105,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 16:51 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001562180-22-005354 · primarydocument.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-23 F3 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 16:51 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005354 · primarydocument.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:10 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantStock Option (Right to Buy) · Derivative | 46,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001209191-22-035015 · doc4.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Ordinary Shares · 46,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 7, 2023 or the date of the 2023 Annual General Meeting of the Company. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 16:45 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Options (Right to buy) · Derivative | 52,320 | $0.00 Strike: $21.97 | $0.00 |
DisclosureSEC source: 0001562180-21-004400 · primarydocument.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,320 Underlying: Common Stock · 52,320 shares Expires 2031-06-17 F1 · derivative.exercise_date: The stock option will vest in thirty-six monthly installments at the end of each successive month following June 17, 2021, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 21:02 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0001209191-21-041506 · doc4.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 40,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 16, 2022 or the date of the 2022 Annual General Meeting of the Company. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 22,464 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018664 · doc4.xml · derivative · entry 6 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,464 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 34,416 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018664 · doc4.xml · derivative · entry 5 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 34,416 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 3,144 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0000899243-21-018664 · doc4.xml · derivative · entry 4 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,144 shares Expires not disclosed F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4 · derivative.expiration_date: These stock options were granted with automatic vesting on exercisable date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 16,548 | Not disclosed Strike: $14.33 | Not disclosed |
DisclosureSEC source: 0000899243-21-018664 · doc4.xml · derivative · entry 3 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 16,548 shares Expires 2029-03-01 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerShare Options · Derivative | 35,340 | Not disclosed Strike: $11.17 | Not disclosed |
DisclosureSEC source: 0000899243-21-018664 · doc4.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 35,340 shares Expires 2028-01-03 F3 · price: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F3 · derivative.exercise_date: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Disposition to issuerOrdinary Shares | 10,584 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018664 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2 · price: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:43 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionShare Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009227 · doc4.xml · derivative · entry 3 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,144 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:43 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 1,260 | $17.85 | $22,491.00 |
DisclosureSEC source: 0000899243-21-009227 · doc4.xml · nonDerivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,584 F3 · kind: Mandatory withhold to cover vested RSU style share options. F4 · shares: Represented by ADS. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:43 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 3,144 | $0.00 | $4.40 |
DisclosureSEC source: 0000899243-21-009227 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of March 1, 2021. Read SEC document |
| February 22, 2021 Filed Feb 25, 2021 09:36 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 22,464 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-008161 · doc4.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,464 Underlying: Ordinary Shares · 22,464 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. Inadvertently late filing. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F3 · derivative.exercise_date: These share options will vest in three equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F4 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F3 · derivative.expiration_date: These share options will vest in three equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting. F4 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionShare Options · Derivative | 3,576 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-000785 · doc4.xml · derivative · entry 3 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4 Underlying: Ordinary Shares · 3,576 shares Expires 2021-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.37 U.S. Dollars as of January 3, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 1,440 | $9.62 | $13,852.80 |
DisclosureSEC source: 0000899243-21-000785 · doc4.xml · nonDerivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 F4 · kind: Mandatory withhold to cover vested RSU style share options. F5 · shares: Represented by ADS. F6 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:31 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 3,576 | $0.00 | $5.01 |
DisclosureSEC source: 0000899243-21-000785 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.37 U.S. Dollars as of January 3, 2020. F3 · balance_after: Excluding 9,868 ordinary shares underlying RSU-style share options previously reported in Column 5 of Table I, of which 3,580 ordinary shares vested on January 4, 2021 and 6,288 ordinary shares have not vested. Excluding 8 ordinary shares erroneously included in Column 5 of Table I of previous form 4s. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:21 UTC | Orchard Therapeutics plc ORTX · Entity 94933 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $7.81 | $0.00 |
DisclosureSEC source: 0001209191-20-037926 · doc4.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 17, 2021 or the date of the 2021 Annual General Meeting of the Company. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 34,416 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015692 · doc4.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,416 Underlying: Ordinary Shares · 34,416 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F3 · derivative.exercise_date: These share options will vest in three equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. F3 · derivative.expiration_date: These share options will vest in three equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:02 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 1,296 | $8.34 | $10,808.64 |
DisclosureSEC source: 0000899243-20-006996 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,440 F1 · kind: Automatic sale to cover vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 17:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 1,536 | $8.53 | $13,102.08 |
DisclosureSEC source: 0000899243-20-000727 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,736 F1 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: The price reported in Column 4 is a weighted average price per ordinary share ($102.35 per ADS). These share were sold in multiple transactions at prices ranging from $8.51 per ordinary share ($102.10 per ADS) to $8.53 per ordinary share ($102.36 per ADS), inclusive. The Reporting Person understands to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 13, 2019 Filed Apr 12, 2019 17:30 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 900 | $14.20 | $12,780.00 |
DisclosureSEC source: 0000899243-19-010609 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,272 F1 · shares: Represented by American Depositary Shares of the Issuer ("ADSs"). Each ADS represents twelve ordinary shares of the Issuer. Inadvertently late filing. F2 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:10 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006342 · doc4.xml · derivative · entry 4 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:10 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006342 · doc4.xml · derivative · entry 3 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:10 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006342 · doc4.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:10 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 16,548 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0000899243-19-006342 · doc4.xml · derivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,548 Underlying: Ordinary Shares · 16,548 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · security: The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · derivative.exercise_price: The exercise price reported is price per ordinary share converted from price per ADS ($172.01). Read SEC document |
| January 03, 2019 Filed Mar 15, 2019 21:23 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 3,580 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008036 · doc4.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of March 13, 2019. F1 · shares: Vesting of restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018. These ordinary shares are subsequently converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Inadvertently late filing. F4 · derivative.exercise_date: The reporting person's Form 3 filed on October 1, 2018 contained stock options to purchase 10,740 ordinary shares vesting on January 3, 2021 and expiring on March 15, 2022. These securities are restricted stock units with a nominal exercise price and vest automatically upon vesting date. The correct vesting schedule of these restricted stock units is as follows: 3,580 ordinary shares vested on January 3, 2019; 3,580 ordinary shares will vest on January 3, 2020; and 3,580 ordinary shares will vest on January 3, 2021. The remaining securities following the reported transaction are reported in Column 5 of Table I. F4 · derivative.expiration_date: The reporting person's Form 3 filed on October 1, 2018 contained stock options to purchase 10,740 ordinary shares vesting on January 3, 2021 and expiring on March 15, 2022. These securities are restricted stock units with a nominal exercise price and vest automatically upon vesting date. The correct vesting schedule of these restricted stock units is as follows: 3,580 ordinary shares vested on January 3, 2019; 3,580 ordinary shares will vest on January 3, 2020; and 3,580 ordinary shares will vest on January 3, 2021. The remaining securities following the reported transaction are reported in Column 5 of Table I. F4 · balance_after: The reporting person's Form 3 filed on October 1, 2018 contained stock options to purchase 10,740 ordinary shares vesting on January 3, 2021 and expiring on March 15, 2022. These securities are restricted stock units with a nominal exercise price and vest automatically upon vesting date. The correct vesting schedule of these restricted stock units is as follows: 3,580 ordinary shares vested on January 3, 2019; 3,580 ordinary shares will vest on January 3, 2020; and 3,580 ordinary shares will vest on January 3, 2021. The remaining securities following the reported transaction are reported in Column 5 of Table I. Read SEC document |
| January 03, 2019 Filed Mar 15, 2019 21:23 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 3,580 | $0.00 | $4.65 |
DisclosureSEC source: 0000899243-19-008036 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Vesting of restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018. These ordinary shares are subsequently converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Inadvertently late filing. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of March 13, 2019. F3 · balance_after: Includes 7,160 and 9,432 ordinary shares underlying restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018 and Form 4 filed on March 5, 2019, respectively. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:18 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Disposition to issuerNonqualified Stock Option (right to buy) · Derivative | 225,000 | Not disclosed Strike: $7.59 | Not disclosed |
DisclosureSEC source: 0001209191-18-046782 · doc4.xml · derivative · entry 4 Secor Alicia · CIK 0001584516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2023-07-20 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:18 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 127,500 | Not disclosed Strike: $5.15 | Not disclosed |
DisclosureSEC source: 0001209191-18-046782 · doc4.xml · derivative · entry 3 Secor Alicia · CIK 0001584516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 127,500 shares Expires 2024-03-03 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:18 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 110,000 | Not disclosed Strike: $7.90 | Not disclosed |
DisclosureSEC source: 0001209191-18-046782 · doc4.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2025-02-09 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 16:18 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Disposition to issuerCommon Stock | 103,855 | $11.50 | $1,194,332.50 |
DisclosureSEC source: 0001209191-18-046782 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price"). F2 · shares: Includes 87,650 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 87,650 restricted stock units was cancelled in exchange for the Offer Price. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 16:58 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | Tax withholdingCommon Stock | 1,870 | $8.80 | $16,456.00 |
DisclosureSEC source: 0001209191-18-017344 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,355 Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:12 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantEmployee Stock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001209191-18-009523 · doc4.xml · derivative · entry 2 Secor Alicia · CIK 0001584516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common stock, $0.01 par value per share · 110,000 shares Expires 2028-02-09 F2 · derivative.exercise_date: The option will be exercisable in 25% increments of the shares on each annual anniversary of the date of the grant. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 16:12 UTC | JUNIPER PHARMACEUTICALS INC JNP · Entity 164322 | GrantCommon Stock | 50,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009523 · doc4.xml · nonDerivative · entry 1 Secor Alicia · CIK 0001584516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,225 F1 · kind: This Restricted Stock Unit Award shall vest 25% on each anniversary of the date of grant over 4 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.